Epstein-Barr virus latency antigen peptide-Major Histocompatibility Complex (EBV pMHC) (EBV pMHC)

Peptide-MHC (pMHC) complexes presenting Epstein-Barr virus (EBV) latency antigens, including Latent Membrane Proteins (LMP1, LMP2), BamHI-A Rightward Frame 1 (BARF1), and Epstein-Barr Nuclear Antigen 1 (EBNA1), are critical targets for immunotherapeutic intervention in EBV-associated diseases. These complexes consist of short viral peptide fragments bound to Major Histocompatibility Complex (MHC) molecules on the surface of infected or malignant cells [1: Young & Rickinson, 2004]. The recognition of these pMHCs by the T-cell receptor (TCR) of cytotoxic T-lymphocytes (CTLs) is the fundamental mechanism for the immune system to identify and eliminate EBV-transformed cells [2: Bollard & Heslop, 2016]. In malignancies such as nasopharyngeal carcinoma (NPC), Hodgkin lymphoma, and post-transplant lymphoproliferative disorder (PTLD), the virus expresses specific latency proteins that are processed and presented as pMHC targets [3: Seto et al., 2005]. Therapeutic strategies targeting these complexes primarily involve adoptive cell therapies, such as tabelecleucel, which utilizes allogeneic EBV-specific T-cells to recognize and kill cells presenting these viral antigens [4: Prockop et al., 2020]. Other approaches include TCR-engineered T-cells and TCR-like antibodies designed to bind these pMHC complexes with high specificity. A significant challenge in targeting these complexes is the requirement for HLA matching, as the peptides are presented only by specific MHC alleles, such as HLA-A*02:01 or HLA-A*11:01 [5: Taylor et al., 2004]. Safety concerns include potential cross-reactivity with self-peptides (molecular mimicry) and the risk of cytokine release syndrome following T-cell activation [6: Lin et al., 2002].

Other names

EBV-specific pMHCLMP/EBNA1/BARF1-HLA complexesEBV latency antigen-MHC complexEBV-pMHCHLA-peptide complexes (EBV)

T-cell receptor (TCR) mediated recognition and cytotoxic T-lymphocyte (CTL) activation